Discover 427 paid clinical trials in Lexington, Kentucky. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 427
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
for
Acute Myeloid Leukemia,
Location: Lexington KY, Louisville KY, Indianapolis IN,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 59
Code: NCT05554406
Phase 2, Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Lexington KY, Louisville KY, Nashville TN, Urbana IL,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06790693
Phase 3, Recruiting
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
for
Acute Myeloid Leukemia
Location: Lexington KY, Louisville KY, Effingham IL, Easley SC,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 59
Code: NCT05554393
Phase 2, Recruiting
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
for
Carcinoma, Non-Small Cell Lung
Location: Lexington KY, Urbana IL, Canton OH, Fairfax VA,
Sponsor: Genprex, Inc.
Sex: All
Age: 18+
Code: NCT04486833
Phase 1, Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
for
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Location: Lexington KY, Nashville TN, Chattanooga TN, Swansea IL,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06806033
Phase 2, Recruiting
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
for
Cancer
Location: Lexington KY
Sponsor: Rachel Miller
Sex: All
Age: 18+
Code: NCT03089554
Phase 2, Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Lexington KY, Franklin OH, Centerville OH,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 0+
Code: NCT06031688
Phase 2, Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
for
Acute Myeloid Leukemia,
Location: Lexington KY, Louisville KY, Indianapolis IN,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05564390
Phase 2, Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Lexington KY, Franklin OH, Centerville OH,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06616584
Phase 2, Phase 3, Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
for
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study